Pacer Advisors Inc. Has $10.14 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Pacer Advisors Inc. reduced its stake in Thermo Fisher Scientific by 35.4%, selling 11,175 shares and holding 20,384 shares worth approximately $10.1 million as of the latest SEC filing.
• Institutional investors hold 89.23% of Thermo Fisher Scientific's stock, with significant increases in holdings by GAMMA Investing and T. Rowe Price in the first quarter.
• The company declared a quarterly dividend of $0.43 per share, with an annualized dividend yield of 0.36%, set to be paid on October 15th.

Pacer Advisors Inc. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,384 shares of the medical research company's stock after selling 11,175 shares during the quarter. Pacer Advisors Inc.'s holdings in Thermo Fisher Scientific were worth $10,143,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Navigoe LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Finally, Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $2.47 during trading hours on Thursday, hitting $479.75. The stock had a trading volume of 1,356,546 shares, compared to its average volume of 2,515,097. The stock's fifty day simple moving average is $418.15 and its 200 day simple moving average is $468.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $181.10 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 2.58 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the firm posted $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.